Document is current
Any future updates will be listed below
-
Authors
Becker, Bruno https://orcid.org/0000-0002-0720-6082
Nazir, Faisal Hayat
Brinkmalm, Gunnar
Camporesi, Elena
Kvartsberg, Hlin
Portelius, Erik
Boström, Martina
Kalm, Marie
Höglund, Kina
Olsson, Maria
Zetterberg, Henrik
Blennow, Kaj
-
Funding
Funding for this research was provided by:
Swedish and european research councils
Swedish State support for clinical research
Knut och Alice Wallenbergs Stiftelse (SE)
Frimurarstiftelsen
Alzheimerfonden
The Parkinson Research Foundation
Stiftelsen Wilhelm och Martina Lundgrens Vetenskapsfond
Torsten Söderbergs Stiftelse
Hjärnfonden
The Swedish Childhood Cancer Foundation
Stiftelsen för Gamla Tjänarinnor
- License Information
-
More Information
Article History
Received: 23 May 2018
Accepted: 17 August 2018
First Online: 29 August 2018
Ethics approvals
: The animal experiments were approved by the Gothenburg committee of the Swedish Animal Welfare Agency (2013–103).
: Not applicable.
: HZ has served at advisory boards of Eli Lilly and Roche Diagnostics, has received travel support from Teva and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. KB has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. The other authors report no conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
